id
stringlengths
9
11
source
stringclasses
1 value
title
stringlengths
15
560
text
stringlengths
2k
153k
PMC5450133
core_pubmed_pmc
Eprinomectin pour-on (EPRINEX® Pour-on, Merial): efficacy against gastrointestinal and pulmonary nematodes and pharmacokinetics in sheep
Eprinomectin pour-on (EPRINEX® Pour-on, Merial): efficacy against gastrointestinal and pulmonary nematodes and pharmacokinetics in sheep Abstract Abstract Background The anthelmintic efficacy of the 0.5% w / v topical formulation of eprinomectin (EPN), EPRINEX® Pour-on (Merial) when administered at 1 mg/kg body weight ...
PMC9774893
core_pubmed_pmc
Pharmacokinetic/Pharmacodynamic Analysis of Continuous-Infusion Fosfomycin in Combination with Extended-Infusion Cefiderocol or Continuous-Infusion Ceftazidime-Avibactam in a Case Series of Difficult-to-Treat Resistant Pseudomonas aeruginosa Bloodstream Infections and/or Hospital-Acquired Pneumonia
Pharmacokinetic/Pharmacodynamic Analysis of Continuous-Infusion Fosfomycin in Combination with Extended-Infusion Cefiderocol or Continuous-Infusion Ceftazidime-Avibactam in a Case Series of Difficult-to-Treat Resistant Pseudomonas aeruginosa Bloodstream Infections and/or Hospital-Acquired Pneumonia Abstract Abstract Ob...
PMC11533912
core_pubmed_pmc
Preclinical Investigation of [ 212 Pb]Pb-DOTAM-GRPR1 for Peptide Receptor Radionuclide Therapy in a Prostate Tumor Model
Preclinical Investigation of [ 212 Pb]Pb-DOTAM-GRPR1 for Peptide Receptor Radionuclide Therapy in a Prostate Tumor Model Abstract Abstract The role of gastrin-releasing peptide receptor (GRPR) in various diseases, including cancer, has been extensively studied and has emerged as a promising therapeutic target. In this ...
PMC4664507
core_pubmed_pmc
New concepts and challenges in the clinical translation of cancer preventive therapies: the role of pharmacodynamic biomarkers
New concepts and challenges in the clinical translation of cancer preventive therapies: the role of pharmacodynamic biomarkers Abstract Abstract Implementation of therapeutic cancer prevention strategies has enormous potential for reducing cancer incidence and related mortality. Trials of drugs including tamoxifen and ...
PMC7485952
core_pubmed_pmc
A Practice‐Based, Clinical Pharmacokinetic Study to Inform Levetiracetam Dosing in Critically Ill Patients Undergoing Continuous Venovenous Hemofiltration (PADRE‐01)
A Practice‐Based, Clinical Pharmacokinetic Study to Inform Levetiracetam Dosing in Critically Ill Patients Undergoing Continuous Venovenous Hemofiltration (PADRE‐01) Abstract Abstract Limited data exist on the effect of continuous renal replacement therapy (CRRT) methods on anti‐epileptic drug pharmacokinetics (PK). Th...
PMC10842193
core_pubmed_pmc
Experimental and mathematical approaches for drug delivery for the treatment of wet age-related macular degeneration
Experimental and mathematical approaches for drug delivery for the treatment of wet age-related macular degeneration Abstract Several chronic eye diseases affect the posterior segment of the eye. Among them age-related macular degeneration can cause vision loss if left untreated and is one of the leading causes of visu...
PMC8484145
core_pubmed_pmc
Pharmacokinetics and safety of niraparib in patients with moderate hepatic impairment
Pharmacokinetics and safety of niraparib in patients with moderate hepatic impairment Abstract Purpose The purpose of this study is to characterize niraparib pharmacokinetics (PK) and safety in patients with normal hepatic function (NHF) versus moderate hepatic impairment (MHI). Methods Patients with advanced solid tum...
PMC5071638
core_pubmed_pmc
Pharmacokinetic evaluation of Shenfu Injection in beagle dogs after intravenous drip administration
Pharmacokinetic evaluation of Shenfu Injection in beagle dogs after intravenous drip administration Abstract Abstract Shenfu Injection (SFI) is a well-defined Chinese herbal formulation that is obtained from red ginseng and processed aconite root. The main active constituents in SFI are ginsenosides and aconitum alkalo...
PMC7930490
core_pubmed_pmc
Modeling and Simulation to Support Phase Ib/IIa Dose Selection for WBP216, A Long Half-Life Fully Human Monoclonal Antibody Against Interleukin-6
Modeling and Simulation to Support Phase Ib/IIa Dose Selection for WBP216, A Long Half-Life Fully Human Monoclonal Antibody Against Interleukin-6 Abstract Abstract WBP216 is an innovative IL-6 antibody, presenting high affinity to IL-6 and a long half-life (40–60 days). To optimize the dosage regimen for future clinica...
PMC3646160
core_pubmed_pmc
A multicenter trial evaluating retaspimycin HCL (IPI-504) plus trastuzumab in patients with advanced or metastatic HER2-positive breast cancer
A multicenter trial evaluating retaspimycin HCL (IPI-504) plus trastuzumab in patients with advanced or metastatic HER2-positive breast cancer Abstract Heat shock protein 90 (Hsp90) facilitates maturation and stability of HER2. Combining an Hsp90 inhibitor and trastuzumab has demonstrated anti-tumor effects in patients...
PMC11224899
core_pubmed_pmc
Enhancing drug administration flexibility: evaluation of pharmacokinetic properties of tegoprazan orally disintegrating tablet (ODT) administered via nasogastric tube or oral dosing
Enhancing drug administration flexibility: evaluation of pharmacokinetic properties of tegoprazan orally disintegrating tablet (ODT) administered via nasogastric tube or oral dosing Abstract Abstract Tegoprazan orally disintegrating tablet (ODT) formulation is a novel formulation to improve a convenience in comparison ...
PMC12272311
core_pubmed_pmc
A Joint Pharmacometric Model of Iohexol and Creatinine Administered through a Meat Meal to Assess GFR and Renal OCT2/MATE Activity
A Joint Pharmacometric Model of Iohexol and Creatinine Administered through a Meat Meal to Assess GFR and Renal OCT2/MATE Activity Abstract Accurately assessing glomerular filtration rate (GFR) from plasma creatinine concentrations is challenging in patients with unstable renal function. This study aimed to refine the ...
PMC12820431
core_pubmed_pmc
Unveiling the Antimicrobial Potential of Ricinus communis: A Comprehensive Review of Its Relevance to Surgical Site Infection (SSI) Pathogens
Unveiling the Antimicrobial Potential of Ricinus communis: A Comprehensive Review of Its Relevance to Surgical Site Infection (SSI) Pathogens Abstract Surgical site infections (SSIs) remain a major global healthcare challenge, significantly affecting postoperative recovery, prolonging hospital stays, and increasing hea...
PMC6299426
core_pubmed_pmc
Gut-brain axis metabolic pathway regulates antidepressant efficacy of albiflorin
Gut-brain axis metabolic pathway regulates antidepressant efficacy of albiflorin Abstract Abstract The gut microbiota is increasingly recognized to influence brain function through the gut-brain axis. Albiflorin, an antidepressant natural drug in China with a good safety profile, is difficult to absorb and cannot be de...
PMC7935833
core_pubmed_pmc
Safety, pharmacodynamic, and pharmacokinetic characterization of vericiguat: results from six phase I studies in healthy subjects
Safety, pharmacodynamic, and pharmacokinetic characterization of vericiguat: results from six phase I studies in healthy subjects Abstract Purpose To characterize the safety, pharmacodynamics, and pharmacokinetics (PK) of vericiguat in healthy males. Methods Six phase I studies were conducted in European, Chinese, and ...
PMC4866074
core_pubmed_pmc
Malaria prevalence, severity and treatment outcome in relation to day 7 lumefantrine plasma concentration in pregnant women
Malaria prevalence, severity and treatment outcome in relation to day 7 lumefantrine plasma concentration in pregnant women Abstract Background Day 7 plasma concentrations of lumefantrine (LF) can serve as a marker to predict malaria treatment outcome in different study populations. Two main cut-off points (175 and 280...
PMC8752110
core_pubmed_pmc
Physiologically based pharmacokinetic modeling for dose optimization of quinine–phenobarbital coadministration in patients with cerebral malaria
Physiologically based pharmacokinetic modeling for dose optimization of quinine–phenobarbital coadministration in patients with cerebral malaria Abstract Abstract Patients with cerebral malaria with polymorphic Cytochrome P450 2C19 ( CYP2C19 ) genotypes who receive concurrent treatment with quinine are at risk of inade...
PMC6385784
core_pubmed_pmc
Modeling and simulation of the endogenous CYP3A induction marker 4β-hydroxycholesterol during enasidenib treatment
Modeling and simulation of the endogenous CYP3A induction marker 4β-hydroxycholesterol during enasidenib treatment Abstract Abstract Background Enasidenib (IDHIFA ® , AG-221) is a first-in-class, targeted inhibitor of mutant IDH2 proteins for treatment of relapsed or refractory acute myeloid leukemia. This was a Phase ...
PMC9310641
core_pubmed_pmc
Translational Pharmacology of PRAX‐944, a Novel T‐Type Calcium Channel Blocker in Development for the Treatment of Essential Tremor
Translational Pharmacology of PRAX‐944, a Novel T‐Type Calcium Channel Blocker in Development for the Treatment of Essential Tremor Abstract Abstract Background Essential tremor is the most common movement disorder with clear unmet need. Mounting evidence indicates tremor is caused by increased neuronal burst firing an...
PMC12192077
core_pubmed_pmc
Leveraging Neural ODEs for Population Pharmacokinetics of Dalbavancin in Sparse Clinical Data
Leveraging Neural ODEs for Population Pharmacokinetics of Dalbavancin in Sparse Clinical Data Abstract This study investigates the use of Neural Ordinary Differential Equations (NODEs) as an alternative to traditional compartmental models and Nonlinear Mixed-Effects (NLME) models for drug concentration prediction in ph...
PMC10310851
core_pubmed_pmc
Efficacy, safety and pharmacokinetics of Unecritinib (TQ-B3101) for patients with ROS1 positive advanced non-small cell lung cancer: a Phase I/II Trial
Efficacy, safety and pharmacokinetics of Unecritinib (TQ-B3101) for patients with ROS1 positive advanced non-small cell lung cancer: a Phase I/II Trial Abstract Abstract This phase I/II trial characterized the tolerability, safety, and antitumor activities of unecritinib, a novel derivative of crizotinib and a multi-ty...
PMC7839293
core_pubmed_pmc
Ebola virus antibody decay–stimulation in a high proportion of survivors
Ebola virus antibody decay–stimulation in a high proportion of survivors Abstract Abstract Neutralizing antibody function provides a foundation for the efficacy of vaccines and therapies 1 – 3 . Here, using a robust in vitro Ebola virus (EBOV) pseudo-particle infection assay and a well-defined set of solid-phase assays...
PMC3944115
core_pubmed_pmc
Evaluating Systems Pharmacology Models Is Different From Evaluating Standard Pharmacokinetic–Pharmacodynamic Models
Evaluating Systems Pharmacology Models Is Different From Evaluating Standard Pharmacokinetic–Pharmacodynamic Models Abstract Abstract Based on the author's recent experience, there appears to be some confusion regarding the steps required to qualify a systems pharmacology model as adequate for the intended purpose. Thi...
PMC7270334
core_pubmed_pmc
An Optimal Control Framework for the Automated Design of Personalized Cancer Treatments
An Optimal Control Framework for the Automated Design of Personalized Cancer Treatments Abstract One of the key challenges in current cancer research is the development of computational strategies to support clinicians in the identification of successful personalized treatments. Control theory might be an effective app...
PMC4917987
core_pubmed_pmc
Multistrain models predict sequential multidrug treatment strategies to result in less antimicrobial resistance than combination treatment
Multistrain models predict sequential multidrug treatment strategies to result in less antimicrobial resistance than combination treatment Abstract Abstract Background Combination treatment is increasingly used to fight infections caused by bacteria resistant to two or more antimicrobials. While multiple studies have e...
PMC8419156
core_pubmed_pmc
A first‐in‐human, randomized, double‐blind, single‐ and multiple‐dose, phase I study of recombinant human thymosin β4 in healthy Chinese volunteers
A first‐in‐human, randomized, double‐blind, single‐ and multiple‐dose, phase I study of recombinant human thymosin β4 in healthy Chinese volunteers Abstract Abstract The study evaluated the safety, tolerability, pharmacokinetics (PK) and anti‐drug antibody (ADA) of the recombinant human thymosin β4 (NL005) for single a...
PMC11330179
core_pubmed_pmc
Time‐varying covariates, overadjustment bias and mediation in pharmacokinetic/pharmacodynamic modeling
Time‐varying covariates, overadjustment bias and mediation in pharmacokinetic/pharmacodynamic modeling Methods MEDIATION ANALYSIS Interestingly, the difference we see in the estimated slope between model A and model B is directly associated with the percentage of the total effect that is mediated by the time‐varying co...
PMC5673638
core_pubmed_pmc
Pharmacodynamics, Pharmacokinetics, and Antiviral Activity of BAY 81-8781, a Novel NF-κB Inhibiting Anti-influenza Drug
Pharmacodynamics, Pharmacokinetics, and Antiviral Activity of BAY 81-8781, a Novel NF-κB Inhibiting Anti-influenza Drug Abstract Abstract Influenza is a respiratory disease that causes annual epidemics. Antiviral treatment options targeting the virus exist, but their efficiency is limited and influenza virus strains ea...
PMC8975762
core_pubmed_pmc
Population Pharmacokinetics of Elagolix in Combination with Low-Dose Estradiol/Norethindrone Acetate in Women with Uterine Fibroids
Population Pharmacokinetics of Elagolix in Combination with Low-Dose Estradiol/Norethindrone Acetate in Women with Uterine Fibroids Abstract Abstract Background and Objectives Elagolix is an orally active, gonadotropin-releasing hormone receptor antagonist approved for the management of endometriosis-associated pain an...
PMC10384610
core_pubmed_pmc
Combining nonsense mutation suppression therapy with nonsense-mediated decay inhibition in neurofibromatosis type 1
Combining nonsense mutation suppression therapy with nonsense-mediated decay inhibition in neurofibromatosis type 1 Abstract Neurofibromatosis type 1 (NF1) results from germline mutations in the tumor-suppressor gene NF1 and predisposes patients to developing nervous system tumors. Twenty percent of NF1 patients harbor...
PMC12939473
core_pubmed_pmc
Plant-Derived Secondary Metabolites Modulating Inflammation-Driven Pathways in Hepatocellular Carcinoma: Preclinical Insights
Plant-Derived Secondary Metabolites Modulating Inflammation-Driven Pathways in Hepatocellular Carcinoma: Preclinical Insights Abstract Hepatocellular carcinoma (HCC) is a leading cause of cancer-related mortality worldwide, primarily driven by chronic inflammation from viral hepatitis, metabolic dysfunction, alcohol-in...
PMC12382847
core_pubmed_pmc
Optimising Regimen of Co-Amoxiclav (ORCA)—The Safety and Efficacy of Intravenous Co-Amoxiclav at Higher Dosing Frequency in Patients with Diabetic Foot Infection
Optimising Regimen of Co-Amoxiclav (ORCA)—The Safety and Efficacy of Intravenous Co-Amoxiclav at Higher Dosing Frequency in Patients with Diabetic Foot Infection Abstract Background : With increasing pharmacokinetic evidence suggesting the inadequacy of conventional dose intravenous co-amoxiclav (IVCA) 1.2 g Q8H in tar...
PMC4303923
core_pubmed_pmc
Long-term phenological trends, species accumulation rates, aphid traits and climate: five decades of change in migrating aphids
Long-term phenological trends, species accumulation rates, aphid traits and climate: five decades of change in migrating aphids Abstract 1. Aphids represent a significant challenge to food production. The Rothamsted Insect Survey (RIS) runs a network of 12·2-m suction-traps throughout the year to collect migrating aphi...
PMC10786731
core_pubmed_pmc
Pharmacokinetics, Safety, and Tolerability of Anti-SARS-CoV-2 Monoclonal Antibody, Sotrovimab, Delivered Intravenously or Intramuscularly in Japanese and Caucasian Healthy Volunteers
Pharmacokinetics, Safety, and Tolerability of Anti-SARS-CoV-2 Monoclonal Antibody, Sotrovimab, Delivered Intravenously or Intramuscularly in Japanese and Caucasian Healthy Volunteers Abstract Abstract Background and Objective Sotrovimab 500 mg administered by a single intravenous (IV) infusion has been granted special ...
PMC12506459
core_pubmed_pmc
Pharmacokinetics and safety of subcutaneous nivolumab: results from the phase I/II CheckMate 8KX study
Pharmacokinetics and safety of subcutaneous nivolumab: results from the phase I/II CheckMate 8KX study Abstract Abstract Background CheckMate 8KX was a phase I/II study investigating the pharmacokinetics and safety of subcutaneous (SC) nivolumab±recombinant human hyaluronidase PH20 (rHuPH20). Methods Patients with adva...
PMC6175176
core_pubmed_pmc
Exposure‐Response (Efficacy) Analysis of Daclatasvir and Asunaprevir in Japanese Patients With Hepatitis C Virus Infection
Exposure‐Response (Efficacy) Analysis of Daclatasvir and Asunaprevir in Japanese Patients With Hepatitis C Virus Infection Abstract Abstract The treatment of hepatitis C virus (HCV) infection has been revolutionized by the development of all‐oral combination regimens of direct‐acting antiviral agents. The current analy...
PMC8492877
core_pubmed_pmc
Population pharmacokinetic model of cefazolin in total hip arthroplasty
Population pharmacokinetic model of cefazolin in total hip arthroplasty Abstract Abstract Cefazolin is an antibiotic recommended for infection prevention in total hip arthroplasty (THA). However, the dosing regimen necessary to achieve therapeutic concentrations in obese patients remains unclear. The aim of this study ...
PMC5021756
core_pubmed_pmc
Pharmacokinetic Modeling and Dose Selection in a Randomized, Double-Blind, Placebo-Controlled Trial of a Human Recombinant Alkaline Phosphatase in Healthy Volunteers
Pharmacokinetic Modeling and Dose Selection in a Randomized, Double-Blind, Placebo-Controlled Trial of a Human Recombinant Alkaline Phosphatase in Healthy Volunteers Abstract Abstract Background and Objective Previous clinical trials have suggested that bovine intestinal alkaline phosphatase has renal protective effect...
PMC6291635
core_pubmed_pmc
Pharmacokinetics of sodium thiosulfate in Guinea pig perilymph following middle ear application
Pharmacokinetics of sodium thiosulfate in Guinea pig perilymph following middle ear application Abstract Abstract Hypothesis To determine the pharmacokinetics of sodium thiosulfate in the inner ear perilymph following middle ear application in Guinea pigs. Background Cisplatin chemotherapy is often associated with a do...
PMC9787715
core_pubmed_pmc
Isopropyl Gallate, a Gallic Acid Derivative: In Silico and In Vitro Investigation of Its Effects on Leishmania major
Isopropyl Gallate, a Gallic Acid Derivative: In Silico and In Vitro Investigation of Its Effects on Leishmania major Abstract Isopropyl gallate (IPG) is a polyphenol obtained from alterations in the gallic acid molecule via acid catalysis with previously reported leishmanicidal and trypanocidal activities. The present ...
PMC12010074
core_pubmed_pmc
FGF1 as a New Promising Therapeutic Target in Type 2 Diabetes: Advances in Research and Clinical Trials
FGF1 as a New Promising Therapeutic Target in Type 2 Diabetes: Advances in Research and Clinical Trials Abstract Abstract Type 2 diabetes mellitus (T2DM) represents a global health crisis, characterized by insulin resistance, β-cell dysfunction, and metabolic disturbances. Current treatments, such as insulin and metfor...
PMC7146003
core_pubmed_pmc
Integrating Pharmacokinetics and Pharmacodynamics in Operational Research to End Tuberculosis
Integrating Pharmacokinetics and Pharmacodynamics in Operational Research to End Tuberculosis Abstract Abstract Tuberculosis (TB) elimination requires innovative approaches. The new Global Tuberculosis Network (GTN) aims to conduct research on key unmet therapeutic and diagnostic needs in the field of TB elimination us...
PMC10537356
core_pubmed_pmc
Analyzing the Material Basis of Anti-RSV Efficacy of Lonicerae japonicae Flos Based on the PK-PD Model
Analyzing the Material Basis of Anti-RSV Efficacy of Lonicerae japonicae Flos Based on the PK-PD Model Abstract Abstract Lonicerae japonicae Flos (LJF) possesses a good anti-respiratory syncytial virus (RSV) effect. However, the material basis of LJF in treating RSV is still unclear. In this study, a sensitive and accu...
PMC11172583
core_pubmed_pmc
Long-Term Pharmacokinetic Follow-Up of Abiraterone Acetate in Patients with Metastatic Castration-Resistant Prostate Cancer
Long-Term Pharmacokinetic Follow-Up of Abiraterone Acetate in Patients with Metastatic Castration-Resistant Prostate Cancer Abstract Abstract This ABIGENE pharmacokinetic (PK) study sought mainly to characterize the unchanged drug PK during long-term abiraterone acetate (AA) administration in advanced prostate cancer p...
PMC4369756
core_pubmed_pmc
Developing Exposure/Response Models for Anticancer Drug Treatment: Special Considerations
Developing Exposure/Response Models for Anticancer Drug Treatment: Special Considerations Abstract Anticancer agents often have a narrow therapeutic index (TI), requiring precise dosing to ensure sufficient exposure for clinical activity while minimizing toxicity. These agents frequently have complex pharmacology, and ...
PMC3852159
core_pubmed_pmc
Population Pharmacokinetics of Lumefantrine in Pregnant and Nonpregnant Women With Uncomplicated Plasmodium falciparum Malaria in Uganda
Population Pharmacokinetics of Lumefantrine in Pregnant and Nonpregnant Women With Uncomplicated Plasmodium falciparum Malaria in Uganda Abstract Abstract Pregnancy alters the pharmacokinetic properties of many antimalarial compounds. The objective of this study was to evaluate the pharmacokinetic properties of lumefan...
PMC6515841
core_pubmed_pmc
Switching thrombopoietin receptor agonist treatments in patients with primary immune thrombocytopenia
Switching thrombopoietin receptor agonist treatments in patients with primary immune thrombocytopenia Abstract Abstract Primary immune thrombocytopenia (ITP) is a bleeding disorder that conventionally has been treated with steroids or other immunosuppressive treatments. The introduction of thrombopoietin receptor agoni...
PMC11015085
core_pubmed_pmc
In silico modeling and simulation of organ‐on‐a‐chip systems to support data analysis and a priori experimental design
In silico modeling and simulation of organ‐on‐a‐chip systems to support data analysis and a priori experimental design Abstract Abstract Organ‐on‐a‐chip (OoC) systems are a promising new class of in vitro devices that can combine various tissues, cultured in different compartments, linked by media flow. The properties ...
PMC4024411
core_pubmed_pmc
Genus Caulophyllum : An Overview of Chemistry and Bioactivity
Genus Caulophyllum : An Overview of Chemistry and Bioactivity Abstract Abstract Recently, some promising advances have been achieved in understanding the chemistry, pharmacology, and action mechanisms of constituents from genus Caulophyllum . Despite this, there is to date no systematic review of those of genus Cauloph...
PMC12389513
core_pubmed_pmc
Pharmacodynamic-Driven Sequence-Dependent Synergy Effects in Pemetrexed-Osimertinib Combination Against Non-Small Cell Lung Cancer (NSCLC): Optimizing Synergy Through Sequential Interval
Pharmacodynamic-Driven Sequence-Dependent Synergy Effects in Pemetrexed-Osimertinib Combination Against Non-Small Cell Lung Cancer (NSCLC): Optimizing Synergy Through Sequential Interval Abstract Background: Combining pemetrexed (PEM) with Osimertinib (OSI) improves outcomes in epidermal growth factor receptor (EGFR)-m...
PMC6502977
core_pubmed_pmc
Orally Administered Crocin Protects Against Cerebral Ischemia/Reperfusion Injury Through the Metabolic Transformation of Crocetin by Gut Microbiota
Orally Administered Crocin Protects Against Cerebral Ischemia/Reperfusion Injury Through the Metabolic Transformation of Crocetin by Gut Microbiota Abstract Abstract Our pilot study suggested that orally administered crocin was hardly absorbed into circulatory system, but it was effective against cerebral ischemic/repe...
PMC7268043
core_pubmed_pmc
Ketamine effects on default mode network activity and vigilance: A randomized, placebo‐controlled crossover simultaneous fMRI/EEG study
Ketamine effects on default mode network activity and vigilance: A randomized, placebo‐controlled crossover simultaneous fMRI/EEG study Abstract Abstract In resting‐state functional connectivity experiments, a steady state (of consciousness) is commonly supposed. However, recent research has shown that the resting stat...
PMC9868209
core_pubmed_pmc
Ceftolozane–Tazobactam Pharmacokinetics in the Abdominal Tissue of Patients Undergoing Lower Gastrointestinal Surgery: Dosing Considerations Based on Site-Specific Pharmacodynamic Target Attainment
Ceftolozane–Tazobactam Pharmacokinetics in the Abdominal Tissue of Patients Undergoing Lower Gastrointestinal Surgery: Dosing Considerations Based on Site-Specific Pharmacodynamic Target Attainment Abstract Abstract Introduction Recently, complicated intra-abdominal infections (cIAI) have been caused not only by Escher...
PMC6328617
core_pubmed_pmc
CD44v6 engages in colorectal cancer progression
CD44v6 engages in colorectal cancer progression Abstract Abstract CD44 is a transmembrane glycoprotein. When the CD44 gene is expressed, its pre-messenger RNA (mRNA) can be alternatively spliced into mature mRNAs that encode several CD44 isoforms. The mRNA assembles with ten standard exons, and the sixth variant exon e...
PMC4859413
core_pubmed_pmc
Pharmacokinetics and aqueous humor penetration of levofloxacin 1.5% and moxifloxacin 0.5% in patients undergoing cataract surgery
Pharmacokinetics and aqueous humor penetration of levofloxacin 1.5% and moxifloxacin 0.5% in patients undergoing cataract surgery Abstract Purpose The objective of this study was to compare the pharmacokinetics of levofloxacin 1.5% and moxifloxacin hydrochloride 0.5% ophthalmic solutions in aqueous humor after multiple...
PMC8148066
core_pubmed_pmc
Gut microbiota mediates the absorption of FLZ, a new drug for Parkinson's disease treatment
Gut microbiota mediates the absorption of FLZ, a new drug for Parkinson's disease treatment Abstract Abstract The gut microbiota plays an important role in regulating the pharmacokinetics and pharmacodynamics of many drugs. FLZ, a novel squamosamide derivative, has been shown to have neuroprotective effects on experime...
PMC11425692
core_pubmed_pmc
Safety, pharmacokinetics, and pharmacodynamics of efzimfotase alfa, a second-generation enzyme replacement therapy: phase 1, dose-escalation study in adults with hypophosphatasia
Safety, pharmacokinetics, and pharmacodynamics of efzimfotase alfa, a second-generation enzyme replacement therapy: phase 1, dose-escalation study in adults with hypophosphatasia Abstract Abstract Hypophosphatasia (HPP) is a rare, inherited metabolic disease caused by deficient activity of tissue-nonspecific alkaline p...
PMC5306220
core_pubmed_pmc
The pharmacokinetics and pharmacodynamics of alogliptin in children, adolescents, and adults with type 2 diabetes mellitus
The pharmacokinetics and pharmacodynamics of alogliptin in children, adolescents, and adults with type 2 diabetes mellitus Abstract Purpose The aim of this study is to determine the pharmacokinetics (PK) and pharmacodynamics (PD) of a single 12.5- or 25-mg dose of alogliptin, a dipeptidyl peptidase-4 (DPP-4) inhibitor,...
PMC5330189
core_pubmed_pmc
Pharmacokinetic interactions between glimepiride and rosuvastatin in healthy Korean subjects: does the SLCO1B1 or CYP2C9 genetic polymorphism affect these drug interactions?
Pharmacokinetic interactions between glimepiride and rosuvastatin in healthy Korean subjects: does the SLCO1B1 or CYP2C9 genetic polymorphism affect these drug interactions? Abstract Abstract To improve cardiovascular outcomes, dyslipidemia in patients with diabetes needs to be treated. Thus, these patients are likely ...
PMC9785263
core_pubmed_pmc
Engineering of a Fully Human Anti-MUC-16 Antibody and Evaluation as a PET Imaging Agent
Engineering of a Fully Human Anti-MUC-16 Antibody and Evaluation as a PET Imaging Agent Abstract Abstract Antibodies that recognize cancer biomarkers, such as MUC16, can be used as vehicles to deliver contrast agents (imaging) or cytotoxic payloads (therapy) to the site of tumors. MUC16 is overexpressed in 80% of epith...
PMC3792011
core_pubmed_pmc
Atazanavir–bilirubin interaction: a pharmacokinetic–pharmacodynamic model
Atazanavir–bilirubin interaction: a pharmacokinetic–pharmacodynamic model Abstract Abstract Purpose The aim of this work was to analyze the atazanavir–bilirubin relationship, using a new mathematical approach to pharmacokinetic–pharmacodynamic models, for competitive drug interactions based on Michaelis–Menten equation...
PMC10311851
core_pubmed_pmc
Florfenicol sustained-release granules: an in vitro-in vivo correlation study in pigs
Florfenicol sustained-release granules: an in vitro-in vivo correlation study in pigs Abstract The objective of this study was to synthesize and characterize pharmaceutical characteristics of florfenicol sustained-release granules (FSRGs) in vitro and in vivo. FSRGs were synthesized using monostearate, polyethylene gly...
PMC7827486
core_pubmed_pmc
The Influence of Body Composition on the Systemic Exposure of Paclitaxel in Esophageal Cancer Patients
The Influence of Body Composition on the Systemic Exposure of Paclitaxel in Esophageal Cancer Patients Abstract Abstract Changes in body composition are associated with chemotherapy-related toxicities and effectiveness of treatment. It is hypothesized that the pharmacokinetics (PK) of chemotherapeutics may depend on bo...
PMC9652259
core_pubmed_pmc
Evaluation of Absorption and Metabolism-Based DDI Potential of Pexidartinib in Healthy Subjects
Evaluation of Absorption and Metabolism-Based DDI Potential of Pexidartinib in Healthy Subjects Abstract Background and Objective Pexidartinib is a novel oral small-molecule inhibitor that selectively targets colony-stimulating factor 1 receptor, KIT proto-oncogene receptor tyrosine kinase, and FMS-like tyrosine kinase...
PMC5115179
core_pubmed_pmc
A pharmacokinetic evaluation and metabolite identification of the GHB receptor antagonist NCS‐382 in mouse informs novel therapeutic strategies for the treatment of GHB intoxication
A pharmacokinetic evaluation and metabolite identification of the GHB receptor antagonist NCS‐382 in mouse informs novel therapeutic strategies for the treatment of GHB intoxication Abstract Abstract Gamma‐aminobutyric acid (GABA) is an endogenous inhibitory neurotransmitter and precursor of gamma‐hydroxybutyric acid (...
PMC9656986
core_pubmed_pmc
Cyclodextrin-Based Polymeric Materials Bound to Corona Protein for Theranostic Applications
Cyclodextrin-Based Polymeric Materials Bound to Corona Protein for Theranostic Applications Abstract Abstract Cyclodextrins (CDs) are cyclic oligosaccharide structures that could be used for theranostic applications in personalized medicine. These compounds have been widely utilized not only for enhancing drug solubili...
PMC12962645
core_pubmed_pmc
Window of opportunity evaluation of blood–brain barrier permeability heterogeneity within and across high-grade glioma patients
Window of opportunity evaluation of blood–brain barrier permeability heterogeneity within and across high-grade glioma patients Abstract Abstract Background Disruption of the blood–brain barrier (BBB) in high-grade brain tumors is characterized by contrast accumulation on diagnostic imaging. This window of opportunity ...
PMC8989842
core_pubmed_pmc
Changes in the Gut Microbiota May Affect the Clinical Efficacy of Oral Anticoagulants
Changes in the Gut Microbiota May Affect the Clinical Efficacy of Oral Anticoagulants Abstract Abstract The mechanism underlying large individual differences in the response to oral anticoagulants has not been fully clarified, and the influence of the intestinal microbiome on exogenous drug metabolism has gradually bec...
PMC7795856
core_pubmed_pmc
PASylated Thymosin α1: A Long-Acting Immunostimulatory Peptide for Applications in Oncology and Virology
PASylated Thymosin α1: A Long-Acting Immunostimulatory Peptide for Applications in Oncology and Virology Abstract Abstract Thymosin α1 (Tα1) is an immunostimulatory peptide for the treatment of hepatitis B virus (HBV) and hepatitis C virus (HCV) infections and used as an immune enhancer, which also offers prospects in ...
PMC4717258
core_pubmed_pmc
Sulfoxides, Analogues of L-Methionine and L-Cysteine As Pro-Drugs against Gram-Positive and Gram-Negative Bacteria
Sulfoxides, Analogues of L-Methionine and L-Cysteine As Pro-Drugs against Gram-Positive and Gram-Negative Bacteria Abstract The problem of resistance to antibiotics requires the development of new classes of broad-spectrum antimicrobial drugs. The concept of pro-drugs allows researchers to look for new approaches to ob...
PMC7032158
core_pubmed_pmc
Evaluation of the Mrp2-mediated flavonoid-drug interaction potential of quercetin in rats and in vitro models
Evaluation of the Mrp2-mediated flavonoid-drug interaction potential of quercetin in rats and in vitro models Abstract Abstract Quercetin is a biologically active flavonoid that has been used as a popular health supplement. It is reported that quercetin may cause flavonoid-drug interaction mediated by P-glycoprotein, t...
PMC8885933
core_pubmed_pmc
An Evaluation of the Pharmacokinetics, Safety, and Tolerability of Aclidinium/Formoterol Fixed-Dose Combination Administered in Chinese Patients with Moderate-to-Severe Chronic Obstructive Pulmonary Disease
An Evaluation of the Pharmacokinetics, Safety, and Tolerability of Aclidinium/Formoterol Fixed-Dose Combination Administered in Chinese Patients with Moderate-to-Severe Chronic Obstructive Pulmonary Disease Abstract Abstract Background and Objectives The aim of this study was to evaluate the pharmacokinetics, safety, a...
PMC9927148
core_pubmed_pmc
Antituberculosis Macozinone Extended-Release Tablets To Enhance Bioavailability: a Pilot Pharmacokinetic Study in Beagle Dogs
Antituberculosis Macozinone Extended-Release Tablets To Enhance Bioavailability: a Pilot Pharmacokinetic Study in Beagle Dogs Abstract ABSTRACT Macozinone (MCZ; PBTZ169) is a first-in-class antituberculosis clinical-stage benzothiazinone-based drug candidate. Although its efficacy and safety have been strongly proven i...
PMC9143859
core_pubmed_pmc
Rapid Absorption of Naloxone from Eye Drops
Rapid Absorption of Naloxone from Eye Drops Abstract Naloxone as emergency treatment for opioid overdosing can be administered via several routes. However, the available administration methods are invasive or may be associated with incomplete or slow naloxone absorption. We evaluated pharmacokinetics and local toleranc...
PMC9978993
core_pubmed_pmc
Carboxylesterase 1 family knockout alters drug disposition and lipid metabolism
Carboxylesterase 1 family knockout alters drug disposition and lipid metabolism Abstract The mammalian carboxylesterase 1 (Ces1/CES1) family comprises several enzymes that hydrolyze many xenobiotic chemicals and endogenous lipids. To investigate the pharmacological and physiological roles of Ces1/CES1, we generated Ces...
PMC9896679
core_pubmed_pmc
Pharmacokinetics and bioequivalence of Ezetimibe tablet versus Ezetrol®:an open-label, randomized, two-sequence crossover study in healthy Chinese subjects
Pharmacokinetics and bioequivalence of Ezetimibe tablet versus Ezetrol®:an open-label, randomized, two-sequence crossover study in healthy Chinese subjects Abstract Abstract Background Ezetimibe is a new class of antihyperlipidemic agent indicated for the prevention of atherosclerosis disease and for the treatment of h...
PMC12383745
core_pubmed_pmc
The Role of Pharmacogenetic Biomarkers in Pain
The Role of Pharmacogenetic Biomarkers in Pain Abstract Abstract Background/Objectives : Pain—whether acute, chronic, or neuropathic—remains a leading cause of disability and reduced quality of life worldwide. Despite advances in pharmacologic options, interindividual variability in response and susceptibility to adver...
PMC4682460
core_pubmed_pmc
Results of a phase I/II open-label, safety and efficacy trial of coagulation factor IX (recombinant), albumin fusion protein in haemophilia B patients
Results of a phase I/II open-label, safety and efficacy trial of coagulation factor IX (recombinant), albumin fusion protein in haemophilia B patients Abstract Introduction rIX-FP is a coagulation factor IX (recombinant), albumin fusion protein with more than fivefold half-life prolongation over other standard factor I...
PMC12683041
core_pubmed_pmc
Integrative and Emerging Models in Antibody Research: A Comprehensive Review
Integrative and Emerging Models in Antibody Research: A Comprehensive Review Abstract Abstract Antibody research has advanced through the integration of in vivo, in vitro , and in silico models, each offering distinct advantages and limitations. In vivo models, such as traditional animal models and humanized mouse mode...
PMC12783157
core_pubmed_pmc
Randomized, Double-Blind, Phase I Pharmacokinetic Study of Subcutaneous Recombinant Human Superoxide Dismutase (rhSOD) in Healthy Volunteers
Randomized, Double-Blind, Phase I Pharmacokinetic Study of Subcutaneous Recombinant Human Superoxide Dismutase (rhSOD) in Healthy Volunteers Abstract Background Excessive production of reactive oxygen species (ROS), particularly superoxide anion ( \documentclass[12pt]{minimal} \usepackage{amsmath} \usepackage{wasysym} ...
PMC5572351
core_pubmed_pmc
Exposure–Response Analysis of Necitumumab Efficacy in Squamous Non‐Small Cell Lung Cancer Patients
Exposure–Response Analysis of Necitumumab Efficacy in Squamous Non‐Small Cell Lung Cancer Patients Abstract Abstract We sought to describe the exposure–response relationship of necitumumab efficacy in squamous non‐small cell lung cancer patients and evaluate intrinsic and extrinsic patient descriptors that may guide do...
PMC9246016
core_pubmed_pmc
Effects of ginkgo leaf tablet on the pharmacokinetics of rosiglitazone in rats and its potential mechanism
Effects of ginkgo leaf tablet on the pharmacokinetics of rosiglitazone in rats and its potential mechanism Abstract Abstract Context Ginkgo leaf tablet (GLT), a traditional Chinese herbal formula, is often combined with rosiglitazone (ROS) for type 2 diabetes mellitus treatment. However, the drug-drug interaction betwe...
PMC7507549
core_pubmed_pmc
Drug interactions with apixaban: A systematic review of the literature and an analysis of VigiBase, the World Health Organization database of spontaneous safety reports
Drug interactions with apixaban: A systematic review of the literature and an analysis of VigiBase, the World Health Organization database of spontaneous safety reports Abstract Abstract Apixaban, a direct oral anticoagulant, has emerged over the past few years because it is considered to have a low risk of drug‐drug i...
PMC9787406
core_pubmed_pmc
Impact of Albumin Binding Function on Pharmacokinetics and Pharmacodynamics of Furosemide
Impact of Albumin Binding Function on Pharmacokinetics and Pharmacodynamics of Furosemide Abstract Background and Objectives : Albumin binding of the loop diuretic furosemide forms the basis for its transport to the kidney and subsequent tubular secretion, which is a prerequisite for its therapeutic effects. Accordingl...
PMC4906077
core_pubmed_pmc
Development of an S-1 dosage formula based on renal function by a prospective pharmacokinetic study
Development of an S-1 dosage formula based on renal function by a prospective pharmacokinetic study Abstract Background S-1 is an oral anticancer drug, containing tegafur (a prodrug of 5-fluorouracil, 5-FU), 5-chloro-2,4-dihydroxypyridine, and potassium oxonate. As renal dysfunction is known to increase exposure of 5-F...
PMC10867144
core_pubmed_pmc
Pharmacokinetics and pharmacodynamics across infusion rates of intravenously administered nipocalimab: results of a phase 1, placebo-controlled study
Pharmacokinetics and pharmacodynamics across infusion rates of intravenously administered nipocalimab: results of a phase 1, placebo-controlled study Abstract Introduction Nipocalimab is a high-affinity, fully human, aglycosylated, effectorless, immunoglobulin G (IgG) 1 monoclonal antibody that targets the neonatal Fc ...
PMC9025505
core_pubmed_pmc
Development and Characterization of Eudragit ® EPO-Based Solid Dispersion of Rosuvastatin Calcium to Foresee the Impact on Solubility, Dissolution and Antihyperlipidemic Activity
Development and Characterization of Eudragit ® EPO-Based Solid Dispersion of Rosuvastatin Calcium to Foresee the Impact on Solubility, Dissolution and Antihyperlipidemic Activity Abstract Abstract Poor solubility is the major challenge involved in the formulation development of new chemical entities (NCEs), as more tha...
PMC7204735
core_pubmed_pmc
Stereoselective pharmacokinetic study of epiprogoitrin and progoitrin in rats with UHPLC–MS/MS method
Stereoselective pharmacokinetic study of epiprogoitrin and progoitrin in rats with UHPLC–MS/MS method Abstract Highlights • A novel UHPLC–MS/MS method to detect epiprogoitrin/progoitrin in rat plasma. • The method was successfully applied for pharmacokinetic studies. • Stereoselective pharmacokinetic differences were n...
PMC6401501
core_pubmed_pmc
Real-Time Monitoring of Pharmacokinetics of Antibiotics in Biofilms with Raman-Tagged Hyperspectral Stimulated Raman Scattering Microscopy
Real-Time Monitoring of Pharmacokinetics of Antibiotics in Biofilms with Raman-Tagged Hyperspectral Stimulated Raman Scattering Microscopy Abstract Antibiotics resistance developed by biofilms has posed a clinical challenge in the effective treatment of bacterial infections. However, the resistance mechanisms have not ...
PMC11313090
core_pubmed_pmc
Advancements in the Research of New Modulators of Nitric Oxide Synthases Activity
Advancements in the Research of New Modulators of Nitric Oxide Synthases Activity Abstract Nitric oxide (NO) has been defined as the “miracle molecule” due to its essential pleiotropic role in living systems. Besides its implications in physiologic functions, it is also involved in the development of several disease st...
PMC12494138
core_pubmed_pmc
Faecal pharmacokinetics, microbiome, and bile acid changes in healthy subjects given intravenous followed by oral omadacycline; a Phase 1 clinical trial
Faecal pharmacokinetics, microbiome, and bile acid changes in healthy subjects given intravenous followed by oral omadacycline; a Phase 1 clinical trial Abstract Abstract Background There is an urgent need to develop new antimicrobials effective intravenously for Clostridioides difficile infection (CDI). Omadacycline i...
PMC3339294
core_pubmed_pmc
Standard Error of Empirical Bayes Estimate in NONMEM® VI
Standard Error of Empirical Bayes Estimate in NONMEM® VI Abstract The pharmacokinetics/pharmacodynamics analysis software NONMEM® output provides model parameter estimates and associated standard errors. However, the standard error of empirical Bayes estimates of inter-subject variability is not available. A simple and...
PMC12368620
core_pubmed_pmc
Pharmacokinetic Profile and Evaluation of Acute and Subchronic Oral Toxicity of Shikimic Acid in Mice
Pharmacokinetic Profile and Evaluation of Acute and Subchronic Oral Toxicity of Shikimic Acid in Mice Abstract Abstract Shikimic acid, a widely known hydroaromatic compound abundantly found in Illicium verum (commonly known as Chinese star anise), serves as a key intermediate in the synthesis of neuraminidase inhibitor...
PMC9464004
core_pubmed_pmc
Pharmacokinetics, Pharmacodynamics, Safety and Tolerability of Sotagliflozin After Multiple Ascending Doses in Chinese Healthy Subjects
Pharmacokinetics, Pharmacodynamics, Safety and Tolerability of Sotagliflozin After Multiple Ascending Doses in Chinese Healthy Subjects Abstract Abstract Background Sotagliflozin (LX4211) is a dual inhibitor of sodium-glucose cotransporter (SGLT)1 and SGLT2 being investigated to improve glycemic control in adults with ...
PMC3519348
core_pubmed_pmc
Preventive and Protective Properties of Zingiber officinale (Ginger) in Diabetes Mellitus, Diabetic Complications, and Associated Lipid and Other Metabolic Disorders: A Brief Review
Preventive and Protective Properties of Zingiber officinale (Ginger) in Diabetes Mellitus, Diabetic Complications, and Associated Lipid and Other Metabolic Disorders: A Brief Review Abstract Abstract Zingiber officinale (ginger) has been used as herbal medicine to treat various ailments worldwide since antiquity. Recen...
PMC8606109
core_pubmed_pmc
Molecular Mechanisms of Anti-Inflammatory Activities of the Extracts of Ocimum gratissimum and Thymus vulgaris
Molecular Mechanisms of Anti-Inflammatory Activities of the Extracts of Ocimum gratissimum and Thymus vulgaris Abstract Background: A large body of literature suggests that the extracts of Ocimum gratissimum (O . gratissimum) and Thymus vulgaris ( T . vulgaris ) play protective roles against various inflammatory disord...
PMC8165097
core_pubmed_pmc
A Review of Romiplostim Mechanism of Action and Clinical Applicability
A Review of Romiplostim Mechanism of Action and Clinical Applicability Abstract Abstract Thrombocytopenia results from a variety of conditions, including radiation, chemotherapy, autoimmune disease, bone marrow disorders, pathologic conditions associated with surgical procedures, hematopoietic stem cell transplant (HSC...
PMC3974464
core_pubmed_pmc
Clinical experience with once–daily tacrolimus in de novo kidney transplant recipients from living donors in Japan: 1–year follow up
Clinical experience with once–daily tacrolimus in de novo kidney transplant recipients from living donors in Japan: 1–year follow up Abstract Introduction We assessed our clinical experience with de novo kidney transplant recipients from living donors who received once–daily tacrolimus (OD TAC). In addition, we investi...
PMC12151198
core_pubmed_pmc
Characterization of preclinical radio ADME properties of ARV-471 for predicting human PK using PBPK modeling
Characterization of preclinical radio ADME properties of ARV-471 for predicting human PK using PBPK modeling Abstract Proteolysis-targeting chimeras (PROTACs) represent a promising class of drugs that can target disease-causing proteins more effectively than traditional small molecule inhibitors can, potentially revolu...
PMC12682749
core_pubmed_pmc
Nonclinical regulatory considerations for investigational new drug applications for regulatory T cell therapies
Nonclinical regulatory considerations for investigational new drug applications for regulatory T cell therapies Abstract Abstract Since FDA approval of the first chimeric antigen receptor (CAR) T cell therapy in 2017, the landscape of cell-based therapies has widely expanded. This expansion has encompassed both the typ...